By Richard L. Cassin, Published on
The FCPA Blog on October 5th, 2015
The Securities and Exchange Commission said Monday that Bristol-Myers Squibb agreed to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales. – See more at:
http://www.fcpablog.com/blog/2015/10/5/bristol-myers-squibb-pays-14-million-to-resolve-china-fcpa-o.html#sthash.ZWIBgB9U.dpuf
Related Events
The American Conference Institute’s fourth annual Asia-Pacific Summit on Anti-Corruption, Compliance and Risk Management will address innovations in compliance, discuss the best risk mitigation strategies and provide updates on the rapidly evolving anti-corruption landscape in the region, with in-depth discussions of China, Indonesia, India, Malaysia, Philippines, Vietnam and Myanmar.
Click here to learn more.
Tags: Anti-Corruption China, AntiCorruption Singapore, Asia-Pacific, FCPA, Industry news, SEC